dEEGtal

dEEGtal transforms epilepsy diagnosis by offering AI-driven software that analyzes EEG data with precision. It identifies early-stage epilepsy patterns, empowering clinicians for faster intervention

dEEGtal’s AI-powered diagnostic software has demonstrated 65% sensitivity and 90% specificity in detecting epilepsy, validated on a large dataset of 1,500 labeled EEGs. Collaborations with leading epilepsy centers in Switzerland and the USA have further supported the robustness and scalability of the solution. Currently at TRL 4, dEEGtal is progressing rapidly and aims to reach TRL 6 by the closing of its next funding round in 2026, paving the way for clinical trials and market entry as a Class II FDA cleared medical device​​.

dEEGtal is addressing the challenge of delayed and inaccurate epilepsy diagnosis, a critical issue affecting millions of patients globally. Current diagnostic methods, such as visual EEG analysis, often lack sensitivity, leading to misdiagnoses and prolonged delays—sometimes years—before treatment initiation. This delay increases the risk of seizure recurrence, driving bans, and deteriorating quality of life. By leveraging AI to analyze EEG data, dEEGtal provides healthcare professionals with a fast, non-invasive, and precise tool to detect epilepsy early, even when traditional methods fail.

dEEGtal offers an AI-driven diagnostic software that analyzes EEG data to detect patterns invisible to visual assessments, even in EEGs judged normal by an expert reader. Using advanced algorithms, it provides an epilepsy risk score, automated reports, and flagged EEG sections for review. Accessible via a secure web platform, it integrates seamlessly into healthcare workflows, enabling earlier intervention, improving diagnostic accuracy, and enhancing patient outcomes​​.

dEEGtal’s business model combines a flat annual subscription fee with a variable cost per EEG analyzed as the standard approach for most institutions. For smaller healthcare facilities, a pay-per-use model is available, billing the cost of the analysis per patient. This dual model ensures flexibility and scalability while addressing diverse customer needs. Additionally, dEEGtal will seek reimbursement for analyses to enhance accessibility and adapt its pricing structure to fit the specific regulatory and healthcare frameworks of most countries.